secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMGC Holdings Inc. (ELAB)
CIK:        0001840563
Form:       8-K
Filed at:   2026-07-01T11:31:32+00:00
Accession:  0001213900-26-073986
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NorthStrive Biosciences reports positive Phase III results: 4 AI-selected compounds increase ANT1 expression up to 50%
--------------------------------------------------------------------------------

- Four AI-selected compounds (C1, C2, C3, C4) significantly increased ANT1 expression in human skeletal muscle cells.
- Strongest dose-dependent induction: C2 up to +50%, C4 up to +48%, C1 up to +46%, C3 +29% at highest dose.
- Yuva Biosciences recommended advancing the four candidates into a more mature muscle model for confirmatory testing.
- Results validate MitoNova AI platform's ability to identify biologically active small-molecule candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840563/000121390026073986/0001213900-26-073986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840563/000121390026073986/ea0296527-8k_pmgc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-073986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer